This study explores the use of cannabidiol (CBD) as an adjunct to treatment for people with Anorexia Nervosa (AN).
Aims
This study assesses the safety, tolerability, and preliminary therapeutic benefits of a 12-week adjunctive cannabidiol (CBD) regimen in individuals with Anorexia Nervosa (AN) undergoing outpatient psychological treatment. The trial will provide valuable insights into the potential of cannabidiol as a supportive treatment for AN and inform future clinical guidelines and applications.
Background
The CAFTAN trial is investigating the safety and preliminary efficacy of CBD as an adjunctive treatment for individuals with AN. Despite growing interest in cannabinoid-based therapies, their role in AN treatment remains underexplored. This study aims to address that gap by evaluating CBD in a real-world outpatient setting.
Subscribe to our newsletter!
© 2026 InsideOut
InsideOut acknowledges the tradition of custodianship and law of the Country on which the University of Sydney and Charles Perkins Centre campus stands. We pay our respects to those who have cared and continue to care for Country. We are committed to diversifying research and eliminating inequities and discrimination in healthcare. We welcome all people regardless of age, gender, race, size, sexuality, language, socioeconomic status, location or ability.